Page 65 - 台灣肝癌醫學冬季會手冊-1222-V3_Neat
P. 65
Table 1: Comparison of clinical characteristics between HCC patients with BCLC
stage B and those with BCLC stage C
Total BCLC classification
P value
(n=22) B (n=8) C (n=14)
Age, years 67 (39-89) 65 (58-89) 68 (39-86) 0.973
Male, n (%) 20 (90.9) 8 (100%) 12 (85.7) 0.166
Etiology of hepatitis, n (%) 0.842
HBV 11 (50) 4 (50.0) 7 (50.0)
HCV 6 (27.3) 3 (37.5) 3 (21.4)
Alcohol 2 (9.1) 0 2 (14.3)
Unknown 3 (13.6) 1 (12.5) 2 (14.3)
Cirrhosis, n (%) 22 (100) 8 (100) 14 (100) NA
Child-Pugh class, n (%) 0.593
A 18 (81.8) 7 (87.5) 11 (78.6)
B 4 (18.2) 1 (12.5) 3 (21.4)
ALBI grade 0.117
1 3 (13.6) 2 (25.0) 1 (7.1)
2 18 (81.8) 5 (62.5) 13 (92.9)
3 1 (4.5) 1 (12.5) 0
Baseline AFP, ng/ml 191.8 19.2 356.56 0.212
(1.7-30748.9) (4.2-30748.9) (1.7-5503.4)
Previous Nexavar, n (%) 20 (90.9) 7 (87.5) 13 (92.9) 0.679
Nivolumab dosage, n (%) 0.243
≤1 mg/kg 9 (40.9) 2 (25.0) 7 (50.0)
>1mg/kg 13 (59.1) 6 (75.0) 7 (50.0)
Mean OS, month 18.1±2.6 20.5±3.0 14.2±1.7 0.334
Median PFS, month 8.1 (0.9-25.2) 8.2 (1.77-25.2) 7.6 (1.25-19.61) 0.367
Response rate, %
CR 13.6 12.5 14.3 0.906
PR 27.3 25.0 28.6 0.856
SD 31.8 50.2 21.4 0.170
PD 27.3 12.5 35.7 0.220
DCR, % 72.7 87.5 64.3 0.220